Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  MetLife    MET

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in MetLife, Inc. of Class Action Lawsuit and Upcoming Deadline - MET

share with twitter share with LinkedIn share with facebook
share via e-mail
02/17/2018 | 02:01pm CET

NEW YORK, Feb. 17, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MetLife, Inc. ("MetLife" or the "Company") (NYSE: MET) and certain of its officers.   The class action, filed in United States District Court, for the Eastern District of New York, is on behalf of a class consisting of investors who purchased or otherwise acquired MetLife securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased MetLife securities between February 27, 2013, and January 29, 2018, both dates inclusive, you have until April 6, 2018, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here to join this class action]

MetLife provides life insurance, annuities, employee benefits, and asset management products in the United States and internationally.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) MetLife's practices and procedures used to estimate its reserves set aside for annuity and pension payments were inadequate; (2) MetLife had inadequate internal controls over financial reporting; and (3) as a result, Defendants' statements about MetLife's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On December 15, 2017, during aftermarket hours, the Company filed a Form 8-K with the Securities and Exchange Commission ("SEC"), announcing that the Company had been unable to locate some of the Company's annuitant population and planned to provide an update upon the filing of MetLife's Form 10-K for the year ending December 31, 2017.

On December 15, 2017, the Wall Street Journal published an article entitled "MetLife Discloses Failure to Pay Thousands of Workers' Pensions" which discussed the extent and duration of MetLife's failure to pay pension benefits.

On this news, shares of MetLife fell $0.62 per share, or over 1.2%, over the following two trading days to close at $50.79 per share on December 19, 2017, damaging investors.

On January 29, 2018, MetLife issued a press release entitled "MetLife Preannounces Preliminary Fourth Quarter 2017 Earnings, Reschedules Earnings Release and Conference Call", which announced that MetLife would reschedule its earnings releases and conference calls for the fourth quarter of and full year 2017, that the Company had identified material weaknesses in its internal controls, that the Company would have to revise certain of its prior financial statements, and that the SEC and New York Department of Financial Services had made inquiries to MetLife with respect to the foregoing issues.

On this news, shares of MetLife fell $6.28 per share or over 11.6% over the next two trading days to close at $47.67 per share on January 31, 2018, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

Robert S. Willoughby
Pomerantz LLP
[email protected] 
888-476-6529 Ext. 9980

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert--pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-metlife-inc-of-class-action-lawsuit-and-upcoming-deadline--met-300600288.html

SOURCE Pomerantz LLP

© PRNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on METLIFE
02/17Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Me..
02/17METLIFE : CFO John Hele Provides Fourth Quarter, Full Year 2017 Financial Update..
02/17METLIFE : to Invest Tax Savings in Employees
02/17METLIFE : RM LAW Announces Class Action Lawsuit Against MetLife, Inc.
02/16METLIFE : LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Su..
02/16METLIFE INC : Other Events, Financial Statements and Exhibits (form 8-K)
02/16METLIFE : Announces First Quarter 2018 Preferred Stock Dividend Action, Subject ..
02/16THE KLEIN LAW FIRM : Announces Commencement of a Class Action Filed on Behalf of..
02/15METLIFE : IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces an Ongoing In..
More news
News from SeekingAlpha
02/16Tracking David Einhorn's Portfolio - Q4 2017 Update 
02/15WALL STREET BREAKFAST : Stocks Unfazed By U.S. Inflation 
02/15Bank of America's insurance conference on tap 
02/14MetLife (MET) Q4 2017 Results - Earnings Call Transcript 
02/14MetLife, Inc. 2017 Q4 - Results - Earnings Call Slides 
Financials ($)
Sales 2018 62 967 M
EBIT 2018 6 392 M
Net income 2018 5 006 M
Debt 2018 -
Yield 2018 3,56%
P/E ratio 2018 9,88
P/E ratio 2019 9,28
Capi. / Sales 2018 0,78x
Capi. / Sales 2019 0,77x
Capitalization 49 174 M
Duration : Period :
MetLife Technical Analysis Chart | MET | US59156R1086 | 4-Traders
Technical analysis trends METLIFE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 55,1 $
Spread / Average Target 18%
EPS Revisions
Steven Albert Kandarian Chairman, President & Chief Executive Officer
Martin J. Lippert Executive VP-Global Technology & Operations
John C. R. Hele Chief Financial Officer & Executive Vice President
Jacki Goldstein Chief Medical Officer
Cheryl W. Grisé Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
METLIFE-7.63%49 142
AXA1.88%76 643
PRUDENTIAL-4.22%66 740
AFLAC-0.15%34 762